Mounjaro vs Wegovy: Comparing the Weight Loss Powerhouses

Introduction – Two Highly Effective Treatments

If you're researching weight loss injections in the UK, two names dominate the conversation: Wegovy and Mounjaro. Both represent the cutting edge of obesity medicine, delivering results that seemed impossible just a decade ago.

Wegovy (semaglutide 2.4mg) launched in the UK in 2023 amid huge demand—so much that supply shortages plagued access for months. Mounjaro (tirzepatide) arrived shortly after, promising even better results with its innovative dual-hormone mechanism.

Both are now approved by NICE for NHS use in obesity, though access remains limited due to cost and capacity constraints. For most people, private prescriptions are the practical route.

So which should you choose? Let's compare these pharmaceutical powerhouses head-to-head.

Mechanism of Action: Dual vs Single Hormone

The key difference between these medications lies in what they target in your body:

Wegovy (Semaglutide 2.4mg)

• Mimics GLP-1 (glucagon-like peptide-1), a gut hormone released after eating
• Suppresses appetite by acting on hunger centres in the brain
• Slows gastric emptying (food stays in stomach longer, keeping you fuller)
• Improves insulin secretion and reduces glucagon (helps blood sugar control)

Wegovy is essentially a higher-dose version of Ozempic—same drug (semaglutide), but specifically formulated and approved for weight management rather than diabetes.

Mounjaro (Tirzepatide)

• Mimics BOTH GLP-1 and GIP (glucose-dependent insulinotropic polypeptide)
• All the GLP-1 benefits above, plus...
• GIP enhances insulin sensitivity and may improve fat metabolism
• Synergistic effect: The two hormones work together to amplify appetite suppression and metabolic improvements

Weight Loss Outcomes: How Much Can You Lose?

Both medications deliver impressive results. Here's what the clinical trials showed:

Breaking Down the Numbers

For someone weighing 100kg (15st 10lb) at the start:

Medication & Dose	Average Weight Loss	Final Weight	Equivalent
Mounjaro 15mg	22.5kg (3st 7lb)	77.5kg (12st 3lb)	Best in class🏆 WINNER
Mounjaro 10mg	19.5kg (3st 1lb)	80.5kg (12st 9lb)	Excellent result
Wegovy 2.4mg	14.9kg (2st 5lb)	85.1kg (13st 5lb)	Very strong result

Important context:

• These are averages—some people lose significantly more (30%+), others less (5-10%)
• Results depend heavily on lifestyle: proper diet and exercise greatly enhance outcomes
• The ~7-8% difference between Mounjaro and Wegovy may not sound huge, but represents substantial additional weight loss (an extra 7-8kg for a 100kg person)
• Both medications surpass older weight loss drugs (orlistat, liraglutide) by a wide margin
• Weight loss typically plateaus around 68-72 weeks; maintenance becomes the focus thereafter

Side Effects and Differences

Because Wegovy and Mounjaro both target the GLP-1 system, their side effect profiles overlap considerably:

Side Effect	Mounjaro	Wegovy
Nausea	20-30% (dose-dependent)	20-44% (dose-dependent)
Diarrhoea	12-18%	20-30%
Vomiting	8-12%	12-24%
Constipation	10-15%	11-24%
Abdominal pain	8-12%	8-13%
Reduced appetite	Very common (intended)	Very common (intended)
Fatigue	Moderate in some	Moderate in some

Key Takeaways on Side Effects

• Wegovy may cause slightly higher rates of GI side effects in some studies, though experiences vary person-to-person
• Both require slow dose escalation to minimise side effects—you don't jump straight to the highest dose
• Side effects typically peak in the first 2-8 weeks at each new dose level, then improve significantly
• Most people tolerate them well with dietary adjustments (smaller meals, bland foods initially, avoiding greasy/spicy foods)
• Serious side effects are rare but include pancreatitis, gallbladder problems, and allergic reactions

Access in the UK: NHS vs Private

Both Wegovy and Mounjaro face the same challenge: high demand, limited NHS capacity, and supply constraints.

Reality check: Despite NICE approvals, the vast majority of people wanting these medications for weight loss will not qualify for NHS provision—or will face years-long waits. Budget constraints and capacity mean NHS access is tightly controlled.

Private Access & Cost

Dose Phase	Mounjaro (Monthly)	Wegovy (Monthly)
Starting dose	£170-£210	£180-£220
Mid dose	£220-£280	£220-£260
Maintenance (high dose)	£280-£350	£260-£300
12-month estimate	£2,800-£3,600	£2,600-£3,200

Cost considerations:

• Mounjaro is marginally more expensive (£200-400 more per year), but delivers superior weight loss
• Wegovy has faced severe supply shortages, sometimes making it harder to source consistently
• Prices vary between online clinics, private GPs, and specialist weight management services
• Some providers offer subscription models with slight discounts for multi-month commitments

Making a Choice: Who Might Prefer Which?

Choose Mounjaro if:

• You want the maximum weight loss potential available from medication
• You haven't tried a GLP-1 medication before (start with the best)
• You qualify for NHS provision (it's becoming more accessible than Wegovy given the larger rollout)
• The cost difference (£15-30/month extra) is acceptable for superior results
• You have type 2 diabetes alongside obesity (Mounjaro's effects on HbA1c are excellent)

Choose Wegovy if:

• You're already on Ozempic via NHS for diabetes and your GP can switch you to Wegovy
• You've previously used semaglutide and tolerated it well
• Supply/availability of Wegovy is better in your area (regional variation exists)
• Your private clinic or insurance has a partnership making Wegovy more affordable
• You prefer a medication with slightly longer real-world usage data (Wegovy/semaglutide has been studied longer)

Or Try Both (Sequentially)

Some people start with Wegovy (perhaps it was available first, or prescribed for diabetes), then later switch to Mounjaro if they plateau or want to push for greater weight loss. Conversely, if someone has intolerable side effects on Mounjaro, switching to Wegovy might be better tolerated. Work with your doctor to find the right fit.

Frequently Asked Questions

The Bottom Line

Wegovy and Mounjaro represent the pinnacle of pharmaceutical weight loss treatment in 2025. Both deliver results that were unimaginable with medication alone just a few years ago.

Mounjaro holds the edge in pure efficacy—its dual-hormone approach consistently produces greater weight loss in trials. For someone prioritising maximum results and able to access it, Mounjaro is the stronger choice.

Wegovy remains excellent, with proven effectiveness, a slightly longer safety track record, and comparable cost. It's especially valuable if you're already on Ozempic for diabetes and can transition to Wegovy (same drug, higher dose).

Realistically, many people in the UK will take whichever they can access—NHS provision is limited for both, supply varies, and some clinics stock one but not the other. The good news? You can't really go wrong with either. Both are transformative medications when combined with healthy lifestyle habits.

Whichever you choose, remember these medications are tools—powerful ones, but tools nonetheless. The best results come when you combine them with nutritious eating, regular physical activity, adequate sleep, and stress management. They make weight loss dramatically easier, but sustained success requires ongoing commitment to healthy behaviours.